Rapiscan (regadenoson)
- Region
- 🇪🇺 EU
- Active substance
- regadenoson
- Company
- GE Healthcare AS
- Status
- Authorised
- Therapeutic area
- Myocardial Perfusion Imaging
- EU approval
- Mon 06 Sep 2010
- Application
- EMEA/H/C/001176
- ATC
- C01EB21
- Official record
- www.ema.europa.eu
Indication
This medicinal product is for diagnostic use only. Rapiscan is a selective coronary vasodilator for use as a pharmacological stress agent for radionuclide myocardial perfusion imaging (MPI) in adult patients unable to undergo adequate exercise stress.
Regulatory milestones
No milestones recorded in the last year.
Follow Rapiscan
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.